Profile
Edward D.
Wirth worked as the Chief Medical Officer at Asterias Biotherapeutics, Inc. from 2013 to 2019.
Prior to that, he was the Chief Science Officer at InVivo Therapeutics Corp.
in 2012, the Chief Medical Officer at Lineage Cell Therapeutics, Inc., and the Medical Director-Regenerative Medicine Division at Geron Corp.
from 2004 to 2011.
Wirth earned two doctorate degrees from the University of Florida in 1992 and 1994.
Former positions of Edward D. Wirth
| Companies | Position | End |
|---|---|---|
| ASTERIAS BIOTHERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 2019-02-28 |
InVivo Therapeutics Corp.
 InVivo Therapeutics Corp. BiotechnologyHealth Technology InVivo Therapeutics Corp. operates as a medical device company that develops groundbreaking technologies for the treatment of spinal cord injuries. The company was founded by Joseph P. Vacanti and Robert S. Langer, Jr. in 2005 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2012-08-31 |
| GERON CORPORATION | Corporate Officer/Principal | 2011-09-30 |
| LINEAGE CELL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Edward D. Wirth
| University of Florida | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| GERON CORPORATION | Health Technology |
| Private companies | 2 |
|---|---|
InVivo Therapeutics Corp.
InVivo Therapeutics Corp. BiotechnologyHealth Technology InVivo Therapeutics Corp. operates as a medical device company that develops groundbreaking technologies for the treatment of spinal cord injuries. The company was founded by Joseph P. Vacanti and Robert S. Langer, Jr. in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
- Stock Market
- Insiders
- Edward D. Wirth
